HKPD

HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratification of the appointment of Onestop Assurance PAC as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026; Proposal No. 3: The increase of the authorized share capital of the Company from US$100,000 divided into 100,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001. Proposal No. 4: The re-designation and re-classification from ordinary shares of a single class to Class A ordinary shares and Class B ordinary shares. Proposal No. 5: The approval and implementation of the Reverse Share Split and Share Consolidation of the Company’s issued and outstanding Ordinary Shares. Proposal No. 6: The Company’s name be changed from “Hong Kong Pharma Digital Technology Holdings Limited” to “Cellyan Biotechnology Co., Ltd” and the Company’s foreign name be changed from “港药数字科技控股有限公司” to “生研生物公司”. Proposal No. 7: The fourth amended and restated memorandum and articles of association of the Company be adopted. Proposal No. 8: The repurchase by the Company of 7,150,000 Class A Ordinary Shares registered in the name of TUTU Business Services Limited and issue of Class B Ordinary Shares; Proposal No. 9: The adoption and approval of the Hong Kong Pharma Digital Technology Holdings Limited 2025 Equity Incentive Plan; For the full text of the above proposals passed and approved at the 2025 AGM, refer to the Form 6-K furnished to the SEC on December 17, 2025. About Hong Kong Pharma Digital Technology Holdings Limited Hong Kong Pharma Digital Technology Holdings Limited offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited. Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers. For more information, please visit the Company's website: www.9zt.hk. Forward-Looking Statements All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. For investor and media inquiries please contact: Hong Kong Pharma Digital Technology Holdings Limited Media Contact: [email protected] Investor Relations: stella @cell-yan.com

HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023. Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023. Revenue Breakdown: Revenue Breakdown: Six Months ended September 30, 2024 Six Months ended September 30, 2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement and distribution 4,759,301 2,346,931 Consignment sales and other revenue 2,210 15,327 Total Revenue $ 11,091,189 $ 7,009,209 - Supply Chain Services: $6,329,678, up 36.3% from $4,646,951 for the same period in 2023. - Procurement and Distribution: $4,759,301, a 102.7% increase from $2,346,931 for the same period in 2023. - Consignment Sales and Other Revenue: $2,210, down from $15,327 for the same period in 2023. Gross Profit: The gross profit for the period was $1,905,603, a 42.6% increase from $1,335,988 for the same period in 2023. Gross Profit: The gross profit for the period was $1,905,603, a 42.6% increase from $1,335,988 for the same period in 2023. Total Expenses Total Expenses: Increased to $10,066,706 for the six months ended September 30, 2024, up from $6,667,999 for the same period last year. Total Expenses: Increased to $10,066,706 for the six months ended September 30, 2024, up from $6,667,999 for the same period last year. Six Months ended September 30, 2024 Six Months ended September 30, 2023 Changes in inventories of merchandised goods $ 4,513,873 $ 2,171,361 Storage cost 530,012 463,412 Transportation cost 2,619,599 1,046,455 Consumption of packing material 514,714 515,594 Depreciation and amortization 30,153 31,727 Labor cost 1,318,041 1,589,164 Outsourcing expenses 328,755 202,169 Others 211,559 648,117 Total cost of sales, selling, general and administrative expenses $ 10,066,706 $ 6,667,999 Net Income Net Income: The Company achieved a net income of $828,559, a 232.6% increase compared to $249,037 in the same period last year. Net Income: The Company achieved a net income of $828,559, a 232.6% increase compared to $249,037 in the same period last year. Management Commentary Lap Sun Wong, Chief Executive Officer of HKPD, stated, "The Company has delivered a strong performance for the six months ended September 30, 2024, demonstrating our ability to grow in a competitive and evolving market. The significant increase in net revenues reflects the effectiveness of our strategic initiatives to enhance our supply chain and procurement services. Despite the rise in expenses due to increased marketing efforts and workforce expansion, our net income reflects our focus on profitability and operational efficiency." Man Bun Kwok, Chief Financial Officer, added, "While we are pleased with our financial progress, we remain mindful of the importance of maintaining a disciplined cost structure as we scale operations. Our investment in marketing aims to capture additional market share in the OTC pharmaceutical supply chain sector, and we believe these efforts will continue to drive growth in the coming periods." About Hong Kong Pharma Digital Technology Holdings Limited Hong Kong Pharma Digital Technology Holdings Limited offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited ("Joint Cross Border"), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited. Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border's comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers. For more information, please visit the Company's website: www.9zt.hk. Forward-Looking Statements All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. For investor and media inquiries please contact: Hong Kong Pharma Digital Technology Holdings Limited Media Contact: [email protected] Investor Relations: [email protected] Telephone: +852 2618-9289 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Expressed in U.S. dollar, except for the number of shares) For the Six Months Ended September 30, Note 2024 unaudited 2023 unaudited Revenues 7 $ 11,091,189 $ 7,009,209 Cost of revenues 8 (9,185,586) (5,673,221) Gross profit 1,905,603 1,335,988 Other income 9 804 427 Operating expenses: Selling, general and administrative expenses 8 (881,120) (994,778) Other gains/(losses), net 10 1,751 (32,817) Total operating expenses (879,369) (1,027,595) Operating profit 1,027,038 308,820 Financial income 11 1,078 156 Finance costs 11 (49,254) (34,812) Finance costs, net (48,176) (34,656) Profit before income taxes 978,862 274,164 Income tax expense 12 (150,303) (25,127) Net profit for the year 13 828,559 249,037 Less: profit attributable to non-controlling interests - - Profit attributable to owners of the Company 828,559 249,037 Other comprehensive income Foreign currency translation adjustments 20,032 227 Comprehensive income attributable to the Company's shareholders $ 848,591 $ 249,264 Earnings per share Basic and diluted * 15 $ 0.083 $ 0.036 Weighted average number of shares outstanding Basic and diluted * 10,000,000 6,843,000 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Expressed in U.S. dollar, except for the number of shares) September March 31, Note 30, 2024 unaudited 2024 audited ASSETS NON-CURRENT ASSETS: Property and equipment, net 16 119,407 103,242 Intangible assets, net 17 89,299 31,825 Right of use assets, net 25 1,073,857 730,451 TOTAL NON-CURRENT ASSETS 1,282,563 865,518 CURRENT ASSETS: Deferred IPO costs 21 2,161,496 1,260,075 Inventories 18 555,522 933,299 Trade receivables, net 19 4,880,309 3,698,757 Other receivables and prepayments 19 902,406 1,262,351 Amount due from related parties 23 14,755 19,971 Restricted cash 401 7,682 Cash and cash equivalents 20 364,990 619,575 TOTAL CURRENT ASSETS 8,879,879 7,801,710 TOTAL ASSETS $ 10,162,442 $ 8,667,228 LIABILITIES AND EQUITY NON-CURRENT LIABILITIES: Lease liabilities non-current portion 25 200,759 117,836 Longterm bank loan non-current portion 24 1,005,610 1,119,276 TOTAL NON-CURRENT LIABILITIES 1,206,369 1,237,112 CURRENT LIABILITIES: Trade and other payables 22 1,801,047 $ 1,416,182 Tax payable 12 345,742 218,831 Contract liabilities 7 74,877 191,066 Due to related parties 23 239,802 500,677 Lease liabilities – current portion 25 910,714 634,504 Current portion of long-term bank loan 24 231,641 180,493 Short-term bank loan 24 - 34,704 TOTAL CURRENT LIABILITIES 3,603,823 3,176,457 TOTAL LIABILITIES 4,810,192 4,413,569 COMMITMENTS AND CONTINGENCIES - - EQUITY: Ordinary shares, 50,000,000 shares authorized, consisting of 49,501,000 Class A ordinary shares of $0.001 par value per share and 499,000 Class B ordinary shares of $0.001 par value per share * Class A ordinary shares, 9,501,000 and 6,843,000 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively * 26 9,501 9,501 Class B Ordinary shares, 499,000 and nil shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively * 499 499 Additional paid in capital 26 3,017,409 3,017,409 Subscription receivable 26 (50,000) (300,000) Retained earnings 27 2,359,667 1,531,108 Accumulated other comprehensive (loss) income 27 15,174 (4,858) TOTAL SHAREHOLDERS' EQUITY 5,352,250 4,253,659 TOTAL LIABILITIES AND EQUITY $ 10,162,442 $ 8,667,228 View original content:https://www.prnewswire.com/news-releases/hong-kong-pharma-digital-technology-holdings-limited-reports-financial-results-for-the-six-months-ended-september-30-2024-302414115.html SOURCE Hong Kong Pharma Digital Technology Holdings Limited